All of Us Research Program
Do you want to change the future of health? The Froedtert & MCW health network is part of the National Institutes of Health All of Us Research Program. It has a simple mission — speed up health research breakthroughs. To do this, All of Us is asking one million people to share their health information. Learn how you can help make a difference by joining the All of Us Research Program.
28 results for "Cancer" and "Head and Neck Cancers"
Phase II Randomized Trial Of Neo-Adjuvant Chemotherapy Followed By Surgery And Post-Operative Radiation Versus Surgery And Post-Operative Radiation For Organ Preservation Of T3 And T4a Nasal And Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)
Testing the Addition of Chemotherapy to the Treatment of Cancer of the Sinonasal Area
Protocol No
ECOG-EA3163
Sub Category
Head and Neck Cancers
A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-stage, P16-positive, Non-smoking Associated Oropharyngeal Cancer
De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Protocol No
NRG-HN005
Sub Category
Head and Neck Cancers
An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Protocol No
GENENTECH-MYPATHWAY
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Endocrine Cancers
A Phase 1b Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Protocol No
ASTELLAS-8374-CL-0101
Sub Category
Endocrine Cancers
Early Phase/Multiple Disease Site Cancers
Head and Neck Cancers
Gastrointestinal Cancers
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
Protocol No
TORAY-950P1V02
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Molecular Analysis for Therapy Choice (MATCH)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Protocol No
ECOG-EAY131-MATCH
Sub Category
Hematologic/Blood Related Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers
Eye/Orbital Cancers
Endocrine Cancers
Breast Cancers
Brain and Spine Cancers
An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
Effect of Palbociclib with Ovarian Suppression and Letrozole in Neoadjuvant Treatment of Breast Cancer
Protocol No
NSABP-FND-FB-13
Sub Category
Breast Cancers
Phase II Study of IMRT Re-Irradiation With Concurrent/Adjuvant Nivolumab In Patients With Locoregionally Recurrent Or Second Primary Squamous Cell Cancer Of The Head And Neck
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
Protocol No
WINSHIP-4221-17
Sub Category
Head and Neck Cancers
A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors
Protocol No
IOVANCE-IOV-COM-202
Sub Category
Head and Neck Cancers
Thoracic Cancers
Skin Cancers
Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
Comparing Radiation Plus Antibody Therapy to Radiation Plus Immune Therapy in People With Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Protocol No
NRG-HN004
Sub Category
Head and Neck Cancers
Impact of Expiratory Muscle Strength Training (EMST) on Swallowing Function in Persons Undergoing Radiotherapy +/- Chemotherapy for Cancers of the Head and Neck
Impact of EMST on Swallowing Function in Head/Neck Ca Pts Undergoing Radiotherapy +/- Chemotherapy
Protocol No
IIT-PAULOSKI-UWM-EMST
Sub Category
Head and Neck Cancers
A Phase II Study of Neoadjuvant Weekly Carboplatin/Paclitaxel followed by Dose-Dense Doxorubicin/Cyclophosphamide in Patients with Hormone Receptor Negative, HER2 Receptor Negative Breast Cancer
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
Protocol No
WON-UW16112-TNBC
Sub Category
Breast Cancers
A Randomized, Placebo-controlled, Double-blind, Phase II Trial of Nanoparticle Albumin-bound Paclitaxel (Nab-paclitaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-positive, Triple-negative Breast Cancer
Abraxane® With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer
Protocol No
UC-16-0403-TNBC
Sub Category
Breast Cancers
A Pivotal (phase IIb), Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
SGX942 (Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck
Protocol No
SOLIGENIX-IDR-OM-02
Sub Category
Head and Neck Cancers
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination with BI 754091 in Patients with Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients with Non-small Cell Lung Cancer and Other Solid Tumors
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
Protocol No
BI-1381-REFMAL485
Sub Category
Breast Cancers
Early Phase/Multiple Disease Site Cancers
Thoracic Cancers
Sarcoma
Skin Cancers
Prostate and Urologic Cancers
Head and Neck Cancers
Gynecologic Cancers
Gastrointestinal Cancers